CD5 and anemia (phenotype): Within this cohort, elevated LDH levels (P = 0.015), anemia (P = 0.046), CD5 + (P < 0.001), initial treatment response (P = 0.006), and time to relapse > 12 months from the initiation of R-CHOP (P = 0.001) were identified as adverse prognostic factors affecting OS.